Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03589469 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Phase 2 study, sponsored by ADC Therapeutics S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 145
- Enrollment target
NCT03589469 is a Phase 2 study that has completed, run by ADC Therapeutics S.A.. The registered enrollment target is 145 participants.
The verdict
NCT03589469, a Phase 2 study, has completed, sponsored by ADC Therapeutics S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 145 participants
- Enrollment target
Study Summary
The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
Interventions
- DRUG Loncastuximab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03589469
The ClinicalTrials.gov registry entry for NCT03589469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADC Therapeutics S.A., which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Loncastuximab tesirine is the first listed.
NCT03589469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03589469 about?
NCT03589469 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
What is the current status of trial NCT03589469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 145 participants. The study started on 2018-08-01. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT03589469?
The interventions under investigation include: Loncastuximab tesirine (DRUG).
Who is sponsoring clinical trial NCT03589469?
This trial is sponsored by ADC Therapeutics S.A., which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.